Progress of maintenance therapy for advanced nonsmallcell lung cancer

Abstract

Abstract: The efficacy of the standard firstline chemotherapy regimen for advanced nonsmall cell lung cancer (NSCLC) has reached a plateau. Study confirmed that chemotherapy drugs and molecular targeted drug maintenance treatment can prolong the survival of patients with advanced NSCLC. Immunotherapy has become a maintenance treatment for advanced NSCLC, and further research is needed to confirm its efficacy.

Key words: Carcinoma, nonsmallcell lung cancer, Drug therapy, Molecular targeted therapy, Immunotherapy

Wen-Zhen-Ping, HAN Ya-Ling. Progress of maintenance therapy for advanced nonsmallcell lung cancer[J]. Journal of International Oncology, 2016, 43(2): 148-.

References

［1］ Fidias P, Dakhil S, Lyss A, et al. Phase Ⅲ study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced nonsmallcell lung cancer: updated report with survival［J］. J Clin Oncol, 2009, 27(4): 591598. ［2］ Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced nonsmallcell lung cancer given maintenance treatment with pemetrexed versus placebo (H3EMCJMEN): results from a randomised, doubleblind, phase 3 study［J］. Lancet Oncol, 2012,13(3): 292299. DOI: 10.1016/S14702045(11)703394. ［3］ PazAres LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol， 2013, 31(23): 28952902. DOI: 10.1200/JCO.2012.47.1102. ［4］ Perol M, Chouaid C, Perol D, et al. Randomized, phase Ⅲ study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined secondline treatment, after cisplatingemcitabine induction chemotherapy in advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2012, 30(28): 35163524. DOI: 10.1200/JCO.2011.39.9782. ［5］刘萍. 替吉奥维持治疗晚期非小细胞肺癌临床疗效观察［J］. 中国全科医学, 2013, 16(9):10381040. DOI: 10.3969/j.issn.10079572.2013.09.025 ［6］胡欣, 李光明, 文世民, 等. 局部晚期非小细胞肺癌维持化疗的疗效评价［J］. 肿瘤, 2010, 30(4): 343346. DOI: 10.3781/j.issn.10007431.2010.04.015 ［7］马晓丽, 张建清, 杨媚, 等. 厄洛替尼维持治疗晚期非小细胞肺癌的系统评价［J］. 中华肿瘤防治杂志, 2014, 21(10): 786791. ［8］ Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic nonsmallcell lung cancer (INFORM; CTONG 0804): a multicentre, doubleblind randomised phase 3 trial［J］. Lancet Oncol， 2012, 13(5): 466475. DOI: 10.1016/S14702045(12)701171. ［9］ Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase Ⅲ, randomized, placebocontrolled, parallelgroup study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic nonsmallcell lung cancer (INFORM; CTONG 0804)［J］. J Thorac Oncol， 2015, 10(4): 655664. DOI: 10.1097/JTO.0000000000000445. ［10］ Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of firstline bevacizumabbased therapy in advanced nonsquamous nonsmallcell lung cancer (SAiL, MO19390): a phase 4 study［J］. Lancet Oncol， 2010, 11(8):733740. DOI: 10.1016/S14702045(10)701510. ［11］ Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmallcell lung cancer: AVAPERL (M022089)［J］. J Clin Oncol， 2013, 31(24): 30043011. DOI: 10.1200/JCO.2012.42.3749. ［12］ Pirker R, Pereira JR, Szczesma A, et al. Cetuximab plus chemotherapy in patients with advanced nonsmallcell lung cancer (FLEX): an openlabel randomized phase Ⅲ trial ［J］.Lancet, 2009, 373(9674): 15251531. DOI: 10.1016/S01406736(09)605699. ［13］ Shi SB, Ma TH, Li CH et al．Effect of maintenance therapy with dendritic cells: cytokineinduced killer cells in patients with advanced nonsmall cell lung cancer［J］. Tumori, 2012, 98(3): 314319. DOI: 10.1700/1125.12398. ［14］薛鸣, 郭明坤. CIK细胞联合白细胞介素2对非小细胞肺癌患者免疫功能及生命质量的影响［J］. 国际肿瘤学杂志, 2015, 42(2): 8890. DOI:10.3760/cma.j.issn.1673422X.2015.02.003. ［15］ Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage ⅢB or Ⅳ nonsmallcell lung cancer receiving BLP25 liposome vaccine ( LBLP25): phase ⅡB randomized, multicenter, openlabel trial［J］. J Cancer Res Clin Oncol, 2011, 137(9): 13371342. DOI: 10.1007/s0043201110033. ［16］ Butts C, Socinski MA, Mitchell PL, et, al Tecemotide (LBLP25) versus placebo after chemoradiotherapy for stage Ⅲ nonsmallcell lung cancer (START): a randomised, doubleblind, phase 3 trial［J］. Lancet Oncol， 2014, 15(1): 5968. ［17］ Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide (LBLP25)in unresectable stage Ⅲ nonsmallcell lung cancer in the phase Ⅲ START study: updated overall survival and biomarker analyses［J］. Ann Oncol， 2015, 26(6): 11341142. DOI: 10.1093/annonc/mdv104. ［18］ Zitvogel L, Kroemer G. Targeting pd1/pdl1 interactions for cancer immunotherapy［J］. Oncoimmunology, 2012, 1(8): 12231225. DOI: 10.4161/onci.21335. ［19］ Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase Ⅲ study of belagenpumatucelL therapeutic tumor cell vaccine for nonsmall cell lung cancer(NSCLC)［C］. Amsterdam：ESMO, 2013，abstract2.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[5]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[6]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[7]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[8]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[11]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[12]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[13]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[14]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[15]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.